Biocon Ltd. share price target

We recommend BUY' with target price of INR 435 (35x FY22E earnings).

We retain Buy recommendation on the stock of Biocon with a revised PT of Rs. 520. Biologics segment is expected to be a significant growth driver and the company is well placed to harness the opportunities emerging in global biosimilars space. Sturdy growth prospects, strong earnings visibility, healthy balance sheet position and lower debt-equity augur well for the company. The possible listing of its wholly owned subsidiary - Biocon Biologics Limited...

We have increased our target price to INR 505 (PEx 32x to FY23E earnings).

Biocon Ltd is an integrated biotechnology enterprise with a presence in biopharmaceuticals, enzymes, custom research and clinical research. The Company's pharmaceutical products include statins, immune suppressants and anti-diabetic drugs.

Outlook remains intact on new product launches, strong pipeline and limited competition in Biosimilars. Additionally, demographic changes will help drive demand across products. Hence, we maintain our BUY...

Biocon' Q2FY21 revenue grew by 11% vs. our expectation of 15% due to supply chain bottleneck and lower takeoff biosimilars' business in new geographies (covid-19 lockdown). EBITDA margins (22%) decreased by 400 bps on YoY due high R&D; expenses, frorex losses and other expenses.

Q2FY2021 was a soft quarter for Biocon. Revenues from operations grew by 11% y-o-y to Rs 1,745 crore. Adjusted PAT rose by 10.3% y-o-y to Rs. 173.8 crore. Improving traction in existing biosimilars, likely pick up in Semglee, geographical expansion are the key growth drivers for Biologics segment. Biocon has retained its guidance for $1 billion in revenues from the biologics segment...

Biocon Ltd is an integrated biotechnology enterprise with a presence in biopharmaceuticals, enzymes, custom research and clinical research. The Company's pharmaceutical products include statins, immune suppressants and anti-diabetic drugs.